Skip to content

GNRH agonist vs GNRH antagonist in infertility treatment.

Gonadotropin-releasing hormone (GnRH) agonist vs GnRH antagonist in stimulation protocol on ART outcomes in infertile endometriosis patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230403057803N1
Enrollment
120
Registered
2023-04-24
Start date
2023-05-05
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility in endometriosis. Endometriosis

Interventions

Intervention 1: Intervention group: In the antagonist protocol, Cinnal-f® (Follitropin alfa) is injected subcutaneously daily from the second day of the cycle, and then when the follicle size reaches

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients aged between 20 and 40 years Patients with endometriosis without a history of endometriosis surgery Patients with anti-mullerian hormone (AMH) level > 1ng/ml Number of antral follicle count (AFC)>5 Patients with Ca125<200 Absence of untreated endocrine disease

Exclusion criteria

Exclusion criteria: Patients with uterine structural problems such as polyps or fibroids Patients with genetic disorders Patients with a history of poor response to stimulation in previous cycles History of ovarian hyperstimulation syndrome (OHSS)

Design outcomes

Primary

MeasureTime frame
Oocyte and embryo count and quality. Timepoint: One month after the treatment (it is not possible to compare before and after the treatment within groups. we can only compare the two groups after the treatment.). Method of measurement: Embryologist assessment based on microscopic criteria.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSedighe Hosseini

Shahid Beheshti University of Medical Sciences

taleghanihospital@sbmu.ac.ir+98 21 2303 1111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026